Phreesia’s Post-Script Engagement named one of PM360’s 2023 Most Innovative Technologies
11 Enero 2024 - 5:44AM
Business Wire
Phreesia is pleased to announce that the healthcare marketing
industry trade publication PM360 has named the Post-Script
Engagement, Phreesia’s new medication adherence solution, to its
list of 2023 Most Innovative Marketing Technologies or
Services.
Over the last decade, PM360’s annual Innovations Issue has
spotlighted the pharma industry’s most innovative companies,
products, strategies, services and more. Phreesia’s Post-Script
Engagement offering was one of 56 overall honorees, chosen from
hundreds of submissions, and one of just 8 technologies or services
to be recognized for marketing innovation.
PM360 highlighted the Post-Script Engagement’s ability to supply
patients with resources to adhere to their medication as soon as
their prescription is written, whether for the first time or a
refill. The engagement delivers curated content to patients in a
secure manner when their consent is on file, after an
appointment.
“We’re honored to receive this recognition for Post-Script
Engagement and the opportunity it’s introduced to reach patients
with the tools they need to start and stay on treatment,” Kristin
Roberts, VP of Product Management, said. “Phreesia is proud to
offer Post-Script Engagement as part of a medication adherence
product suite that supports patients, providers and life sciences
partners.”
In addition to supporting patients with starting or staying on
treatment, the Post-Script Engagement survey measures how likely
they are to fill their prescription, PM360 noted. The insights
generated from the engagement’s intent-to-fill survey help doctors
tailor their interactions with patients to address their unique
adherence challenges head-on.
“At Phreesia, we’re committed to helping patients take a more
active role in their care and ultimately improve health outcomes,”
David Linetsky, SVP, Life Sciences, said. “We’re very proud that
Post-Script Engagement not only supplies patients with the
resources they need to take their medications as prescribed, but
also facilitates tailored doctor-patient conversations that can
help eliminate barriers to treatment.”
About Phreesia
Phreesia is the trusted leader in patient activation, giving
providers, health plans, life sciences companies and other
organizations tools to help patients take a more active role in
their care. Founded in 2005, Phreesia enabled more than 120 million
patient visits in 2022—more than 1 in 10 visits across the
U.S.—scale that we believe allows us to make meaningful impact.
Offering patient-driven digital solutions for intake, outreach,
education and more, Phreesia enhances the patient experience,
drives efficiency and improves healthcare outcomes. To learn more,
visit phreesia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240111395517/en/
Press Contact Carly Helfand
chelfand@phreesia.com 332-910-6768
Phreesia (NYSE:PHR)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Phreesia (NYSE:PHR)
Gráfica de Acción Histórica
De May 2023 a May 2024